BR112015027373A2 - Processo de expressão - Google Patents

Processo de expressão

Info

Publication number
BR112015027373A2
BR112015027373A2 BR112015027373A BR112015027373A BR112015027373A2 BR 112015027373 A2 BR112015027373 A2 BR 112015027373A2 BR 112015027373 A BR112015027373 A BR 112015027373A BR 112015027373 A BR112015027373 A BR 112015027373A BR 112015027373 A2 BR112015027373 A2 BR 112015027373A2
Authority
BR
Brazil
Prior art keywords
target polypeptide
expression
expression vector
expressing
expression process
Prior art date
Application number
BR112015027373A
Other languages
English (en)
Portuguese (pt)
Inventor
Louise Dodds Anna
Vallabh Kara Bhupendra
Louise Saunders Fay
Marie Geraldine Bayard Adeline
Original Assignee
Fujifilm Diosynth Biotechnologies Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201308017A external-priority patent/GB201308017D0/en
Priority claimed from GB201320339A external-priority patent/GB201320339D0/en
Application filed by Fujifilm Diosynth Biotechnologies Uk Ltd filed Critical Fujifilm Diosynth Biotechnologies Uk Ltd
Publication of BR112015027373A2 publication Critical patent/BR112015027373A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
BR112015027373A 2013-05-03 2014-04-29 Processo de expressão BR112015027373A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201308017A GB201308017D0 (en) 2013-05-03 2013-05-03 Expression process
GB201320339A GB201320339D0 (en) 2013-11-18 2013-11-18 Expression Process
PCT/GB2014/000165 WO2014177826A1 (en) 2013-05-03 2014-04-29 Expression process

Publications (1)

Publication Number Publication Date
BR112015027373A2 true BR112015027373A2 (pt) 2017-08-29

Family

ID=50639794

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015027373A BR112015027373A2 (pt) 2013-05-03 2014-04-29 Processo de expressão

Country Status (12)

Country Link
US (3) US9873891B2 (https=)
EP (1) EP2992104B1 (https=)
JP (1) JP6545153B2 (https=)
KR (1) KR102180660B1 (https=)
CN (2) CN114395584B (https=)
BR (1) BR112015027373A2 (https=)
CA (1) CA2910877C (https=)
DK (1) DK2992104T3 (https=)
ES (1) ES2732907T3 (https=)
RU (1) RU2731717C2 (https=)
SG (1) SG11201508447TA (https=)
WO (1) WO2014177826A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3323826A1 (en) * 2016-11-21 2018-05-23 Danmarks Tekniske Universitet Native chinese hamster ovary cell secretion signal peptides for production of recombinant polypeptides
CN111465686B (zh) 2017-12-11 2024-03-22 富士胶片株式会社 动物细胞、动物细胞的制造方法及靶蛋白的制造方法
WO2020122049A1 (ja) 2018-12-11 2020-06-18 富士フイルム株式会社 動物細胞、動物細胞の製造方法および目的タンパク質の製造方法
CN109837277A (zh) * 2019-03-01 2019-06-04 深圳生生凡非基因技术有限公司 一种cpgk嵌合型启动子、腺相关病毒载体及其应用
WO2021107123A1 (ja) 2019-11-29 2021-06-03 富士フイルム株式会社 細胞培養方法、抗体製造方法、有機酸除去方法、及び、抗体
WO2022149607A1 (ja) 2021-01-07 2022-07-14 富士フイルム株式会社 細胞の選択方法、装置、及び装置システム
WO2022196710A1 (ja) 2021-03-17 2022-09-22 富士フイルム株式会社 細胞培養方法、及び有用物質の製造方法
CN112980852B (zh) * 2021-05-18 2021-08-13 北京华芢生物技术有限公司 新型冠状病毒b.1.351南非突变株rbd的基因及其应用
US20230011134A1 (en) 2021-05-27 2023-01-12 Janssen Biotech, Inc. Compositions and methods for the treatment of prostate cancer
EP4410957A4 (en) 2021-09-30 2026-01-28 Fujifilm Corp CELL CULTURE PROCESS AND PROCESS FOR PRODUCING USEFUL SUBSTANCE
EP4450609A1 (en) 2021-12-15 2024-10-23 FUJIFILM Corporation Method for producing product, and cell culture apparatus
CN118974267A (zh) 2022-03-28 2024-11-15 富士胶片株式会社 产物的生产方法及产物
JPWO2023190829A1 (https=) 2022-03-31 2023-10-05
JPWO2023238949A1 (https=) 2022-06-10 2023-12-14
EP4596704A4 (en) 2022-09-29 2026-03-11 Fujifilm Corp PRODUCT PRODUCTION PROCESS
WO2024248118A1 (ja) 2023-05-31 2024-12-05 富士フイルム株式会社 細胞培養方法および生産物の製造方法
CN121175432A (zh) 2023-05-31 2025-12-19 富士胶片株式会社 生产物的生产方法
EP4722377A1 (en) 2023-05-31 2026-04-08 FUJIFILM Corporation Method for producing product
WO2025244971A1 (en) 2024-05-20 2025-11-27 Janssen Biotech, Inc. Compositions and methods for the treatment of prostate cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003223766A1 (en) * 2002-04-30 2003-11-17 University Of North Carolina At Chapel Hill Secretion signal vectors
US7186699B2 (en) * 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
US8029783B2 (en) * 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
EP1739179A1 (en) * 2005-06-30 2007-01-03 Octapharma AG Serum-free stable transfection and production of recombinant human proteins in human cell lines
GB0602173D0 (en) * 2006-02-03 2006-03-15 Avecia Ltd Expression system
MX2009007139A (es) * 2006-12-28 2009-10-08 Centocor Ortho Biotech Inc Metodos y vectores para generar inmunoglobulinas no sialiladas.
KR101618767B1 (ko) * 2008-09-02 2016-05-09 한국생명공학연구원 외래단백질을 고효율로 생산하는 리더서열
CA2746350C (en) * 2008-12-31 2018-06-12 Bharat Serums And Vaccines Ltd. Anti-rhd monoclonal antibodies
TWI541021B (zh) 2009-03-05 2016-07-11 艾伯維有限公司 Ｉｌ－１７結合蛋白
GB0905331D0 (en) * 2009-03-27 2009-05-13 Avecia Biolog Ltd Expression process
KR101420274B1 (ko) * 2011-06-13 2014-07-21 주식회사 종근당 Ｃｓｐ－ｂ ５＇ｓａｒ 인자를 포함하는 동물세포 발현 벡터 및 이를 이용한 재조합 단백질의 제조방법

Also Published As

Publication number Publication date
US20180127777A1 (en) 2018-05-10
CA2910877A1 (en) 2014-11-06
US20220213500A1 (en) 2022-07-07
DK2992104T3 (da) 2019-07-15
CA2910877C (en) 2021-08-03
RU2015151626A3 (https=) 2018-03-20
CN114395584B (zh) 2025-01-28
EP2992104A1 (en) 2016-03-09
JP6545153B2 (ja) 2019-07-17
SG11201508447TA (en) 2015-11-27
CN114395584A (zh) 2022-04-26
EP2992104B1 (en) 2019-04-17
KR20160003705A (ko) 2016-01-11
US11306323B2 (en) 2022-04-19
JP2016517691A (ja) 2016-06-20
US9873891B2 (en) 2018-01-23
RU2731717C2 (ru) 2020-09-08
WO2014177826A1 (en) 2014-11-06
ES2732907T3 (es) 2019-11-26
US20160076051A1 (en) 2016-03-17
KR102180660B1 (ko) 2020-11-19
CN105392889A (zh) 2016-03-09
RU2015151626A (ru) 2017-06-08

Similar Documents

Publication Publication Date Title
BR112015027373A2 (pt) Processo de expressão
MX371025B (es) Células eucariotas novedosas y métodos para la expresión recombinante de un producto de interés.
GB2502937A (en) Running a plurality of instances of an application
CL2012003014A1 (es) Acido nucleico aislado que codifica un receptor pyr/pyl mutado; polipeptido codificado por dicho acido nucleico; casette y vector de expresión que comprenden el polinucleotido descrito anteriormente y metodo para aumentar la tolerancia al estrés en una planta.
IN2014CN04774A (https=)
JO3519B1 (ar) تركيبات أجسام مضادة لأجل cdh19 و cd3
NZ717647A (en) Structure based predictive modeling
CL2016000232A1 (es) Estabilización de polipéptidos que contienen fragmentos cristalizables
PH12014500949A1 (en) Generating additional merge candidates
BR112019008484A2 (pt) circuito, estação base, método realizado por um processador, e, mídia de gravação.
MX2013012209A (es) Metodo de codificacion de video, aparato de codificacion de video, metodo de decodificacion de video, aparato de decodificacion de video y aparato de codificacion/decodificacion de video.
AR089571A1 (es) Metodos y aparatos de codificacion de datos de video
BR112015030946A2 (pt) composição compreendendo uma célula ß pancreática não-nativa, método de diferenciação de células progenitoras em células ß pancreáticas in vitro e uso de uma célula ß pancreática não-nativa
MX2015012875A (es) Composiciones de cultivo celular con antioxidantes y metodos para la produccion de polipeptidos.
BR112016008830A2 (pt) Método para produzir uma substância alvo
BR112015030435A8 (pt) computador, artigo de fabricação e processo para proporcionar temporizadores por processador virtuais para sistemas de processador múltiplo
GB2523492A (en) System and method for providing for power savings in a processor environment
MX356162B (es) Sistema de expresion y secrecion.
BR112016024895A2 (pt) fator secretório de proteína com alta eficácia secretória e um vetor de expressão compreendendo o mesmo
BR112016012229A2 (pt) métodos de produção de polipeptídeos
AR087103A1 (es) Tecnologia de simulacion integrada
GB201305554D0 (en) Implementing remapping command with indirection update for indirected storage
MX373329B (es) Células eucariotas novedosas y métodos para la expresión recombinante de un producto de interés.
EA202190244A2 (ru) Сверхэкспрессия регуляторов пути n-гликозилирования для модуляции гликозилирования рекомбинантных белков
MX2018007298A (es) Variantes con mejores propiedades de polipéptidos de fusión relacionados con omega-hidroxilasa.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.